Liang Liu1,2, Ping Li3,4, Yiqi Liu1, Yilian Zhang1. 1. School of Graduate, Tianjin Medical University, Tianjin, China. 2. Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China. 3. Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China. tjlplxg@163.com. 4. Tianjin Research Institute of Liver Diseases, Tianjin, China. tjlplxg@163.com.
Abstract
BACKGROUND AND AIM: Extensive epidemiological evidence suggests that nonalcoholic fatty liver disease (NAFLD) is the primary chronic liver disease worldwide. However, some studies have showed conflicting results on the effects of probiotics and synbiotics supplementation. Therefore, we conducted a systematic review and meta-analysis to investigate the effectiveness of the supplementation in subjects with NAFLD. METHODS: We searched systematically PubMed, Cochrane, and Embase databases up to April 2018 and checked manually the bibliography of the original articles. The quality of the studies was evaluated using the Cochrane Risk of Bias Tool. RESULTS: This study analyzed 15 randomized, controlled trials involving 782 patients with NAFLD. Probiotics and synbiotics supplementation could significantly improve liver steatosis, alanine aminotransferase, aspartate aminotransferase, triglyceride, total cholesterol, high-density lipoprotein, low-density lipoprotein, homeostasis model assessment-insulin resistance, liver stiffness and tumor necrosis factor-alpha (all P < 0.05). But the supplementation could not ameliorate body mass index (mean difference [MD] = -0.00; 95% confidence interval [CI]: -0.22 to 0.22, P = 0.99), waist circumference (MD = -0.01; 95% CI -0.03 to 0.02, P = 0.57) and fasting blood sugar (standard mean difference [SMD] = -0.10; 95% CI -0.32 to 0.12, P = 0.39). CONCLUSION: We present clear evidence for the benefit of probiotics and synbiotics supplementation for liver steatosis, liver enzymes, lipid profiles and liver stiffness in patients with NAFLD.
BACKGROUND AND AIM: Extensive epidemiological evidence suggests that nonalcoholic fatty liver disease (NAFLD) is the primary chronic liver disease worldwide. However, some studies have showed conflicting results on the effects of probiotics and synbiotics supplementation. Therefore, we conducted a systematic review and meta-analysis to investigate the effectiveness of the supplementation in subjects with NAFLD. METHODS: We searched systematically PubMed, Cochrane, and Embase databases up to April 2018 and checked manually the bibliography of the original articles. The quality of the studies was evaluated using the Cochrane Risk of Bias Tool. RESULTS: This study analyzed 15 randomized, controlled trials involving 782 patients with NAFLD. Probiotics and synbiotics supplementation could significantly improve liver steatosis, alanine aminotransferase, aspartate aminotransferase, triglyceride, total cholesterol, high-density lipoprotein, low-density lipoprotein, homeostasis model assessment-insulin resistance, liver stiffness and tumor necrosis factor-alpha (all P < 0.05). But the supplementation could not ameliorate body mass index (mean difference [MD] = -0.00; 95% confidence interval [CI]: -0.22 to 0.22, P = 0.99), waist circumference (MD = -0.01; 95% CI -0.03 to 0.02, P = 0.57) and fasting blood sugar (standard mean difference [SMD] = -0.10; 95% CI -0.32 to 0.12, P = 0.39). CONCLUSION: We present clear evidence for the benefit of probiotics and synbiotics supplementation for liver steatosis, liver enzymes, lipid profiles and liver stiffness in patients with NAFLD.
Authors: Saman Khalesi; David Wayne Johnson; Katrin Campbell; Susan Williams; Andrew Fenning; Sonia Saluja; Christopher Irwin Journal: Eur J Nutr Date: 2017-11-08 Impact factor: 5.614
Authors: Giovanni Musso; Roberto Gambino; James H Tabibian; Mattias Ekstedt; Stergios Kechagias; Masahide Hamaguchi; Rolf Hultcrantz; Hannes Hagström; Seung Kew Yoon; Phunchai Charatcharoenwitthaya; Jacob George; Francisco Barrera; Svanhildur Hafliðadóttir; Einar Stefan Björnsson; Matthew J Armstrong; Laurence J Hopkins; Xin Gao; Sven Francque; An Verrijken; Yusuf Yilmaz; Keith D Lindor; Michael Charlton; Robin Haring; Markus M Lerch; Rainer Rettig; Henry Völzke; Seungho Ryu; Guolin Li; Linda L Wong; Mariana Machado; Helena Cortez-Pinto; Kohichiroh Yasui; Maurizio Cassader Journal: PLoS Med Date: 2014-07-22 Impact factor: 11.069
Authors: Stephan C Bischoff; Rocco Barazzoni; Luca Busetto; Marjo Campmans-Kuijpers; Vincenzo Cardinale; Irit Chermesh; Ahad Eshraghian; Haluk Tarik Kani; Wafaa Khannoussi; Laurence Lacaze; Miguel Léon-Sanz; Juan M Mendive; Michael W Müller; Johann Ockenga; Frank Tacke; Anders Thorell; Darija Vranesic Bender; Arved Weimann; Cristina Cuerda Journal: United European Gastroenterol J Date: 2022-08-12 Impact factor: 6.866
Authors: Ludovico Abenavoli; Luigi Boccuto; Alessandro Federico; Marcello Dallio; Carmelina Loguercio; Laura Di Renzo; Antonino De Lorenzo Journal: Int J Environ Res Public Health Date: 2019-08-21 Impact factor: 3.390
Authors: Jung A Eom; Goo Hyun Kwon; Na Yeon Kim; Eun Ju Park; Sung Min Won; Jin Ju Jeong; Ganesan Raja; Haripriya Gupta; Yoseph Asmelash Gebru; Satyapriya Sharma; Ye Rin Choi; Hyeong Seop Kim; Sang Jun Yoon; Ji Ye Hyun; Min Kyo Jeong; Hee Jin Park; Byeong Hyun Min; Mi Ran Choi; Dong Joon Kim; Ki Tae Suk Journal: Int J Mol Sci Date: 2021-06-13 Impact factor: 5.923